Syncom Formulations (India) Limited (SYNCOMF.BO)
INR 16.66
(3.29%)
INR 16.66
(3.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 249.25 Million INR | 79.51% |
| 2022 | 138.84 Million INR | -5.86% |
| 2021 | 147.48 Million INR | -48.65% |
| 2020 | 287.19 Million INR | 282.07% |
| 2019 | 75.16 Million INR | 124.54% |
| 2018 | 33.47 Million INR | -8.7% |
| 2017 | 36.66 Million INR | -73.21% |
| 2016 | 136.84 Million INR | -9.71% |
| 2015 | 151.57 Million INR | 0.16% |
| 2014 | 151.32 Million INR | 12.25% |
| 2013 | 134.8 Million INR | 68.24% |
| 2012 | 80.12 Million INR | 36.32% |
| 2011 | 58.77 Million INR | 593.51% |
| 2010 | 8.47 Million INR | -88.53% |
| 2009 | 73.87 Million INR | 21.58% |
| 2008 | 60.76 Million INR | 0.97% |
| 2007 | 60.18 Million INR | -13.82% |
| 2006 | 69.83 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 91.54 Million INR | 12.64% |
| 2023 Q4 | 81.26 Million INR | -22.36% |
| 2023 Q3 | 104.66 Million INR | 89.36% |
| 2023 Q2 | 55.27 Million INR | 3.13% |
| 2023 Q1 | 53.59 Million INR | 11.81% |
| 2023 FY | 249.25 Million INR | 79.51% |
| 2022 Q1 | 24.91 Million INR | 182.11% |
| 2022 FY | 138.84 Million INR | -5.86% |
| 2022 Q4 | 47.93 Million INR | 1.91% |
| 2022 Q3 | 47.03 Million INR | 51.34% |
| 2022 Q2 | 31.08 Million INR | 24.75% |
| 2021 Q4 | 8.83 Million INR | -77.4% |
| 2021 Q2 | 46.95 Million INR | -22.1% |
| 2021 Q3 | 39.07 Million INR | -16.79% |
| 2021 FY | 147.48 Million INR | -48.65% |
| 2021 Q1 | 60.27 Million INR | -18.12% |
| 2020 Q3 | 132.52 Million INR | 5.36% |
| 2020 Q4 | 73.61 Million INR | -44.45% |
| 2020 FY | 287.19 Million INR | 282.07% |
| 2020 Q1 | 40.21 Million INR | -2.78% |
| 2020 Q2 | 125.78 Million INR | 212.77% |
| 2019 Q4 | 41.36 Million INR | -9.31% |
| 2019 Q1 | 41.33 Million INR | 28.42% |
| 2019 Q2 | 49.68 Million INR | 20.2% |
| 2019 Q3 | 45.61 Million INR | -8.2% |
| 2019 FY | 75.16 Million INR | 124.54% |
| 2018 Q1 | 19.65 Million INR | -19.14% |
| 2018 FY | 33.47 Million INR | -8.7% |
| 2018 Q4 | 32.18 Million INR | -16.59% |
| 2018 Q3 | 38.59 Million INR | 0.23% |
| 2018 Q2 | 38.5 Million INR | 95.92% |
| 2017 Q2 | 29.49 Million INR | -7.81% |
| 2017 FY | 36.66 Million INR | -73.21% |
| 2017 Q4 | 24.3 Million INR | -36.07% |
| 2017 Q3 | 38.02 Million INR | 28.9% |
| 2017 Q1 | 31.99 Million INR | -3.8% |
| 2016 Q1 | 37.79 Million INR | 37.43% |
| 2016 FY | 136.84 Million INR | -9.71% |
| 2016 Q4 | 33.25 Million INR | 0.0% |
| 2015 Q3 | 46.3 Million INR | -6.68% |
| 2015 Q1 | 28.15 Million INR | -12.86% |
| 2015 Q2 | 49.61 Million INR | 76.22% |
| 2015 FY | 151.57 Million INR | 0.16% |
| 2015 Q4 | 27.5 Million INR | -40.6% |
| 2014 Q3 | 52.53 Million INR | 16.98% |
| 2014 Q1 | 21.57 Million INR | -46.14% |
| 2014 Q2 | 44.9 Million INR | 108.11% |
| 2014 FY | 151.32 Million INR | 12.25% |
| 2014 Q4 | 32.3 Million INR | -38.5% |
| 2013 Q2 | 31.35 Million INR | 37.79% |
| 2013 Q4 | 40.06 Million INR | -1.41% |
| 2013 FY | 134.8 Million INR | 68.24% |
| 2013 Q1 | 22.75 Million INR | 62.54% |
| 2013 Q3 | 40.63 Million INR | 29.63% |
| 2012 Q4 | 13.99 Million INR | -57.26% |
| 2012 Q2 | 27.14 Million INR | 5100.57% |
| 2012 Q3 | 32.75 Million INR | 20.65% |
| 2012 Q1 | 522 Thousand INR | 0.0% |
| 2012 FY | 80.12 Million INR | 36.32% |
| 2011 FY | 58.77 Million INR | 593.51% |
| 2010 FY | 8.47 Million INR | -88.53% |
| 2009 FY | 73.87 Million INR | 21.58% |
| 2008 FY | 60.76 Million INR | 0.97% |
| 2007 FY | 60.18 Million INR | -13.82% |
| 2006 FY | 69.83 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 95.671% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 99.409% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 97.224% |
| Granules India Limited | 6.81 Billion INR | 96.344% |
| Indoco Remedies Limited | 1.29 Billion INR | 80.716% |
| Achyut Healthcare Limited | 4.43 Million INR | -5516.291% |
| Ajanta Pharma Limited | 19.67 Billion INR | 98.733% |
| Alkem Laboratories Limited | 19.46 Billion INR | 98.719% |
| Alpa Laboratories Limited | 184.49 Million INR | -35.098% |
| Brooks Laboratories Limited | 14.44 Million INR | -1626.115% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 85.488% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 79.752% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.632% |
| Eris Lifesciences Limited | 5.18 Billion INR | 95.19% |
| FDC Limited | 2.98 Billion INR | 91.653% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 96.167% |
| Gufic Biosciences Limited | 1.32 Billion INR | 81.258% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 94.362% |
| Ipca Laboratories Limited | 7.98 Billion INR | 96.877% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 50.947% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 264.027% |
| Lasa Supergenerics Limited | -458 Million INR | 154.421% |
| Laurus Labs Limited | 3.94 Billion INR | 93.688% |
| Lupin Limited | 28.04 Billion INR | 99.111% |
| Mankind Pharma Limited | 21.51 Billion INR | 98.842% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -148.505% |
| Megasoft Limited | -121.1 Million INR | 305.816% |
| NATCO Pharma Limited | 25.96 Billion INR | 99.04% |
| Piramal Pharma Limited | 4.55 Billion INR | 94.53% |
| RPG Life Sciences Limited | 2.29 Billion INR | 89.127% |
| Sigachi Industries Limited | 1.47 Billion INR | 83.089% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.761% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 94.59% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | 56.25% |
| Windlas Biotech Limited | 1.29 Billion INR | 80.81% |
| ZIM Laboratories Limited | 253.82 Million INR | 1.804% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 99.422% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 106.057% |
| Divi's Laboratories Limited | 33.08 Billion INR | 99.247% |
| Hester Biosciences Limited | 364.81 Million INR | 31.676% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 91.053% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 45.524% |
| Bal Pharma Limited | 233.9 Million INR | -6.559% |
| Strides Pharma Science Limited | 5.22 Billion INR | 95.23% |
| Venus Remedies Limited | 534.65 Million INR | 53.381% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 92.032% |
| Nectar Lifesciences Limited | 923.8 Million INR | 73.019% |
| Shilpa Medicare Limited | 1.36 Billion INR | 81.757% |
| Aarti Drugs Limited | 7.14 Billion INR | 96.513% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 84.391% |
| Suven Life Sciences Limited | -1.22 Billion INR | 120.333% |
| Ind-Swift Limited | 1.22 Billion INR | 79.669% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 98.255% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 106.469% |
| Themis Medicare Limited | 392.58 Million INR | 36.511% |
| Hikal Limited | 32.11 Million INR | -676.241% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 99.016% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 60.215% |
| Wockhardt Limited | -670 Million INR | 137.202% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 95.197% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -2648.476% |
| Neuland Laboratories Limited | 5.31 Billion INR | 95.313% |
| Morepen Laboratories Limited | 4.17 Billion INR | 94.028% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -19.803% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -807.754% |